voxelotor   Click here for help

GtoPdb Ligand ID: 10559

Synonyms: compound 36 [PMID: 28337324] | GBT-440 | GBT440 | Oxbryta®
Approved drug
voxelotor is an approved drug (FDA (2019), EMA (2022))
Compound class: Synthetic organic
Comment: Voxelotor (GBT440) is an orally bioavailable drug that acts allosterically to stabilise the relaxed (R)-state of sickle cell haemoglobin (HbS) in which it has high affinity for oxygen, and this mechanism reduces the HbS polymerisation that drives erythrocyte sickling [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 77.24
Molecular weight 337.14
XLogP 3.61
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=Cc1c(cccc1O)OCc1cccnc1c1ccnn1C(C)C
Isomeric SMILES O=Cc1c(cccc1O)OCc1cccnc1c1ccnn1C(C)C
InChI InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3
InChI Key FWCVZAQENIZVMY-UHFFFAOYSA-N
References
1. Metcalf B, Chuang C, Dufu K, Patel MP, Silva-Garcia A, Johnson C, Lu Q, Partridge JR, Patskovska L, Patskovsky Y et al.. (2017)
Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin.
ACS Med Chem Lett, 8 (3): 321-326. [PMID:28337324]
2. Vichinsky E, Hoppe CC, Ataga KI, Ware RE, Nduba V, El-Beshlawy A, Hassab H, Achebe MM, Alkindi S, Brown RC et al.. (2019)
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
N Engl J Med, 381 (6): 509-519. [PMID:31199090]